HHE Pathology and diagnostics supplement 2018 | Page 13

References
1 Pantel K, Alix-Panabieres
C. Circulating tumour cells in
cancer patients: challenges and
perspectives. Trends Molec Med
2010;16(9):398–406.
2 Merker JD et al. Circulating
tumor DNA analysis in patients
with cancer: American Society
of Clinical Oncology and College
of American Pathologists
Joint Review. J Clin Oncol
2018:Jco2017768671.
3 Cristofanilli M et al. Circulating
tumor cells, disease progression,
and survival in metastatic
breast cancer. N Engl J Med
2004;351(8):781–91.
4 Cohen SJ et al. Relationship of
circulating tumor cells to tumor
response, progression-free
survival, and overall survival
in patients with metastatic
colorectal cancer. J Clin Oncol
2008;26(19):3213–21.
5 de Bono JS et al. Circulating
tumor cells predict survival
benefit from treatment in
metastatic castration-resistant
prostate cancer. Clin Cancer Res
2008;14(19):6302–9.
6 Zhang L et al. Meta-analysis
of the prognostic value of
circulating tumor cells in
breast cancer. Clin Cancer Res
2012;18(20):5701–10.
7 Bidard FC et al. Clinical validity
of circulating tumour cells in
patients with metastatic breast
cancer: a pooled analysis of
individual patient data. Lancet
Oncol 2014;15(4):406–14.
8 Baccelli I et al. Identification of
a population of blood circulating
tumor cells from breast cancer
patients that initiates metastasis
in a xenograft assay. Nat
Biotechnol 2013;31(6):539–44.
9 Yang L et al. Optimization
of an enrichmen t process for
circulating tumor cells from the
blood of head and neck cancer
patients through depletion of
normal cells. Biotechnol Bioeng
2009;102(2):521–34.
10 Lara O et al. Enrichment
of rare cancer cells through
depletion of normal cells
using density and flow-
through, immunomagnetic
cell separation. Exp Hemetol
2004;32(10):891–904.
11 Alix-Panabieres C, Mader S,
Pantel K. Epithelial-mesenchymal
plasticity in circulating tumor
cells. J Molec Med (Berlin,
Germany) 2017;95(2):133–42.
12 Powell AA et al. Single
cell profiling of circulating
tumor cells: transcriptional
heterogeneity and diversity from
breast cancer cell lines. PLoS One
2012;7(5):e33788.
13 Giordano A et al. Epithelial-
mesenchymal transition and
stem cell markers in patients
with HER2-positive metastatic
breast cancer. Mol Cancer Ther
2012;11(11):2526–34.
14 Ramirez P et al. Oncological
evaluation by positron-emission
tomography, circulating tumor
cells and alpha fetoprotein in
patients with hepatocellular
carcinoma on the waiting list for
liver transplantation. Transplant
Proc 2016;48(9):2962–5.
15 Bredemeier M et al.
Establishment of a multimarker
qPCR panel for the molecular
characterization of circulating
tumor cells in blood samples
of metastatic breast cancer
patients during the course of
palliative treatment. Oncotarget
2016;7(27):41677–90.
16 Autebert J et al. High
purity microfluidic sorting
and analysis of circulating
tumor cells: towards routine
mutation detection. Lab Chip
2015;15(9):2090–101.
17 Karabacak NM et al.
Microfluidic, marker-free
isolation of circulating tumor
cells from blood samples. Nat
Protoc 2014;9(3):694–710.
18 Seal SH. Silicone flotation:
a simple quantitative method
for the isolation of free-floating
cancer cells from the blood.
Cancer 1959;12(3):590–5.
19 Desitter I et al. A new
device for rapid isolation by
size and characterization of
rare circulating tumor cells.
Anticancer Res 2011;31(2):427–
41.
20 Farace F et al. A direct
comparison of CellSearch and
ISET for circulating tumour-cell
detection in patients with
metastatic carcinomas. Br J
Cancer 2011;105(6):847–53.
21 Adams DL et al. The
systematic study of circulating
tumor cell isolation using
lithographic microfilters. RSC
Adv 2014;9:4334–42.
22 Adams DL et al. Cytometric
characterization of circulating
tumor cells captured by
microfiltration and their
correlation to the CellSearch((R))
CTC test. Cytometry A
2015;87(2):137–44.
23 Xu L et al. Optimization
and evaluation of a novel size
based circulating tumor cell
isolation system. PLoS One
2015;10(9):e0138032.
24 Lemaire CA et al. Fast and
label-free isolation of circulating
tumor cells from blood: From a
research microfluidic platform to
an automated fluidic instrument,
VTX-1 Liquid Biopsy System.
SLAS Technol 2018;23(1):16–29.
25 Hou HW et al. Isolation and
retrieval of circulating tumor
cells using centrifugal forces. Sci
Rep 2013;3:1259.
26 Balasubramanian P et al.
Antibody-independent capture
of circulating tumor cells of
non-epithelial origin with the
ApoStream(R) system. PLoS One
2017;12(4):e0175414.
27 Ilie M et al. “Sentinel”
circulating tumor cells allow
early diagnosis of lung cancer in
patients with chronic obstructive
pulmonary disease. PloS One
2014;9(10):e111597.
28 Vona G et al. Isolation
by size of epithelial tumor
cells : a new method for the
immunomorphological and
molecular characterization of
circulatingtumor cells. Am J
Pathol 2000;156(1):57–63.
29 Harouaka RA et al. Flexible
micro spring array device for
high-throughput enrichment
of viable circulating tumor cells.
Clin Chem 2014;60(2):323–33.
30 Sarioglu AF et al. A
microfluidic device for label-free,
physical capture of circulating
tumor cell clusters. Nat Methods
2015;12(7):685–91.
31 Krivacic RT et al. A
rare-cell detector for cancer.
Proc Natl Acad Sci U S A
2004;101(29):10501–4.
32 Somlo G et al. Multiple
biomarker expression on
circulating tumor cells in
comparison to tumor tissues
from primary and metastatic
sites in patients with locally
advanced/inflammatory, and
stage IV breast cancer, using
a novel detection technology.
Breast Cancer Res Treat
2011;128(1):155–63.
33 Ntouroupi TG et al. Detection
of circulating tumour cells
in peripheral blood with
an automated scanning
fluorescence microscope. Br J
Cancer 2008;99(5):789–95.
34 Pailler E et al. Method for
semi-automated microscopy of
filtration-enriched circulating
tumor cells. BMC Cancer
2016;16:477.
35 Lustberg MB et al.
Heterogeneous atypical cell
populations are present in blood
of metastatic breast cancer
patients. Breast Cancer Res
2014;16(2):R23.
36 Zhang L et al. The
identification and
characterization of breast
cancer CTCs competent for
brain metastasis. Sci Transl Med
2013;5(180):180ra48.
37 Heitzer E et al. Complex
tumor genomes inferred from
single circulating tumor cells by
array-CGH and next-generation
sequencing. Cancer Res
2013;73(10):2965–75.
38 Abonnenc M et al.
Programmable interactions of
functionalized single bioparticles
in a dielectrophoresis-based
microarray chip. Anal Chem
2013;85(17):8219–24.
39 Fabbri F et al. Detection
and recovery of circulating
colon cancer cells using a
dielectrophoresis-based
device: KRAS mutation status
in pure CTCs. Cancer Lett
2013;335(1):225–31.
40 Mesquita B et al. Molecular
analysis of single circulating
tumour cells following long-term
storage of clinical samples. Mol
Oncol 2017;11(12):1687–97.
41 Paolillo C et al. Detection of
activating estrogen receptor
gene (ESR1) mutations in single
circulating tumor cells. Clin
Cancer Res 2017;23(20):6086–93.
42 Peeters DJ et al.
Semiautomated isolation and
molecular characterisation
of single or highly purified
tumour cells from CellSearch
enriched blood samples using
dielectrophoretic cell sorting. Br
J Cancer 2013;108(6):1358–67.
43 Esmaeilsabzali H et al.
Detection and isolation of
circulating tumor cells: principles
and methods. Biotechnol Adv
2013;31(7):1063–84.
44 Riethdorf S, Wikman H, Pantel
K. Review: Biological relevance
of disseminated tumor cells in
cancer patients. Int J Cancer
2008;123(9):1991–2006.
45 Fehm T et al. De tection and
characterization of circulating
tumor cells in blood of primary
breast cancer patients by RT-PCR
and comparison to status of
bone marrow disseminated
cells. Breast Cancer Res
2009;11(4):R59.
46 Punnoose EA et al. Molecular
biomarker analyses using
circulating tumor cells. PLoS One
2010;5(9):e12517.
47 Pantel K, Brakenhoff RH,
Brandt B. Detection, clinical
relevance and specific biological
properties of disseminating
tumour cells. Nat Rev Cancer
2008;8(5):329–40.
48 Chebouti I et al. ERCC1-
expressing circulating tumor
cells as a potential diagnostic
tool for monitoring response to
platinum-based chemotherapy
and for predicting post-
therapeutic outcome of
ovarian cancer. Oncotarget
2017;8(15):24303–13.
49 Soler A et al. EpCAM-
Independent enrichment and
detection of viable circulating
tumor cells using the EPISPOT
13
HHE 2018 | hospitalhealthcare.com
assay. Methods Mol Biol
2017;1634:263–76.
50 Cayrefourcq L et
al. Establishment and
characterization of a cell
line from human circulating
colon cancer cells. Cancer Res
2015;75(5):892–901.
51 Deneve E et al. Capture
of viable circulating tumor
cells in the liver of colorectal
cancer patients. Clin Chem
2013;59(9):1384–92.
52 Kuske A et al. Improved
detection of circulating tumor
cells in non-metastatic high-risk
prostate cancer patients. Sci Rep
2016;6:39736.
53 Markou A et al. Multiplex
gene expression profiling of
in vivo isolated circulating
tumor cells in high-risk prostate
cancer patients. Clin Chem
2018;64(2):297–306.
54 Alix-Panabieres C. EPISPOT
assay: detection of viable DTCs/
CTCs in solid tumor patients.
Recent Results Cancer Res
2012;195:69–76.
55 Tulley S et al. Vita-Assay
method of enrichment and
identification of circulating
cancer cells/circulating tumor
cells (CTCs). Methods Mol Biol
2016;1406:107–19.
56 Friedlander TW et al.
Detection and characterization
of invasive circulating tumor
cells derived from men with
metastatic castration-resistant
prostate cancer. Int J Cancer
2014;134(10):2284–93.
57 Lu J et al. Isolation of
circulating epithelial and
tumor progenitor cells with an
invasive phenotype from breast
cancer patients. Int J Cancer
2010;126(3):669–83.
58 Hodgkinson CL et al.
Tumorigenicity and genetic
profiling of circulating tumor
cells in small-cell lung cancer.
Nat Med 2014;20(8):897–903.
59 Riethdorf S et al. Detection
and HER2 expression of
circulating tumor cells:
prospective monitoring in breast
cancer patients treated in the
neoadjuvant GeparQuattro trial.
Clin Cancer Res 2010;16(9):2634–
45.
60 Jaeger BAS et al. The HER2
phenotype of circulating tumor
cells in HER2-positive early
breast cancer: A translational
research project of a prospective
randomized phase III trial. PLoS
One 2017;12(6):e0173593.
61 Topalian SL, Drake CG,
Pardoll DM. Immune checkpoint
blockade: a common
denominator approach to
cancer therapy. Cancer Cell
2015;27(4):450–61.
62 Mazel M et al. Frequent
expression of PD-L1 on
circulating breast cancer cells.
Mol Oncol 2015;9(9):1773–82.
63 Paoletti C et al.
Comprehensive mutation
and copy number profiling
in archived circulating breast
cancer tumor cells documents
heterogeneous resistance
mechanisms. Cancer Res
2018;78(4):1110–22.
64 Sho S et al. Precision
oncology using a limited number
of cells: optimization of whole
genome amplification products
for sequencing applications.
BMC Cancer 2017;17(1):457.
65 Denis JA, Lacorte JM.
Detection of RAS mutations
in circulating tumor cells:
applications in colorectal cancer
and prospects. Ann Biol Clin
(Paris) 2017;75(6):607–18.
66 Obermayr E et al. Circulating
tumor cells: potential markers
of minimal residual disease in
ovarian cancer? a study of the
OVCAD consortium. Oncotarget
2017;8(63):106415–28.
67 Podolak J et al. Androgen
receptor amplification is
concordant between circulating
tumor cells and biopsies from
men undergoing treatment for
metastatic castration resistant
prostate cancer. Oncotarget
2017;8(42):71447–55.